Patent ID: 11944677
Assignee: VERIMMUNE INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 11:
12. The VLP of claim 11, wherein:
a) the at least one antigen is at least a viral antigen, and wherein the viral antigen is from one or more of: vaccinia, Varicella zoster, coronavirus, cytomegalovirus, herpes simplex virus, Herpes zoster, rubella, hepatitis, influenza, measles, mumps, poliovirus, variola, rabies, dengue, Ebola, West Nile, yellow fever, and zika,
b) the at least one antigen is at least a bacterial antigenic peptide, and wherein the bacterial antigen is from one or more of: Bordetella pertussis, Clostridium tetani, Chlamydia trachomatis, Corynebacterium diphtheriae, Hemophilus influenza, Neisseria meningitidis, Streptococcus, Vibrio cholera, Mycobacterium tuberculosis, Bacillus Calmette-Guérin, Salmonella, Escherichia coli, Legionella pneumophila, Rickettsia, Treponema pallidum pallidum, Bacillus anthracis, Clostridium botulinum, and Yersinia, or
c) the at least one antigen is at least a parasitic antigenic peptide, and wherein the parasitic antigen is from one or more of: Entamoeba histolytica, Toxoplasma gondii, Trichinella, Trichomonas, Trypanosoma, and Plasmodium.